


## Supplement 9| Forest Plots


### Key question 1.1.

#### 1.1. All-cause mortality: RCTs

##### 1.1.1. All-cause mortality: events




##### 1.1.2. All-cause mortality: time to event




#### 1.2. All-cause mortality: non-RCTs


##### 1.2.1. All-cause mortality: events (HD)



### 1.2.2. All-cause mortality: time to event (HD)




### 1.2.3. All-cause mortality: 1 mL/min/1.73m<sup>2</sup> GFR greater (HD or PD)




## 1.3. Cost effectiveness: use of resource by group over duration of trial


### 1.3.1. Hospitalization: average days




1.3.2. Hospitalization: average contacts



1.3.3. Non-admitted hospital visits




1.3.4. Visit to health care professional




## 1.4. Adverse events


### 1.4.1. Composite cardiovascular events




### 1.4.2. Composite infectious events (death or hospitalization from infection)




### 1.4.3. Complications of dialysis (need for access revision)




1.4.4. Complication of dialysis (access site infection)



1.4.5. Complication of dialysis (serious fluid or electrolytes disorder)




1.4.6. Complication of dialysis (placement of temporary dialysis catheter)




## 1.5. Echocardiographic data


1.5.1. Echocardiographic endpoint: Left ventricular ejection fraction (%)



1.5.2. Echocardiographic endpoint: Left ventricular mass index (g/m<sup>2</sup>)



1.5.3. Echocardiographic endpoint: Left atrial volume index (mL/m<sup>2</sup>)




## Key question 1.2.


Not applicable

## Key question 2.1.


1.1. All-cause mortality of <4 hours vs ≥4 hours dialysis time per sessions: RCT




1.2. Hospitalization of <4 hours vs ≥4 hours dialysis time per sessions: RCT



1.3. All-cause mortality of <4 hours vs ≥4 hours dialysis time per sessions: non-RCT



1.4. All-cause mortality of 2/week vs 3/week dialysis session: non-RCT




**Key question 2.2.**

Not applicable


**Key question 3.1.**




1.1. High vs. low flux hemodialysis: meta-analysis result on all-cause mortality




1.2. High vs. low flux hemodialysis: meta-analysis result on cardiovascular death




1.3. High vs. low flux hemodialysis: meta-analysis result on hospitalization



1.4. High vs. low flux hemodialysis: meta-analysis result on serum  $\beta_2$ -microglobulin concentration




1.5. High vs. low flux hemodialysis: meta-analysis result on eKt/V




Key question 3.2.

1.1. Impact of OL-HDF on participants with end-stage kidney disease on all-cause mortality.



1.2. Impact of OL-HDF on participants with end-stage kidney disease on all-cause hospitalization.



**Key question 4.1.**


Study or Subgroup	LMWH		UFH		Weight	Risk Ratio	Year
	Events	Total	Events	Total		IV, Random, 95% CI	
Schrader 1988	0	35	0	35		Not estimable	1988
Bambauer 1990	3	27	6	27	24.3%	0.50 [0.14, 1.80]	1990
Nurmohamed 1991	3	35	0	35	10.6%	7.00 [0.37, 130.69]	1991
Saltissi 1999	12	36	6	36	29.2%	2.00 [0.84, 4.75]	1999
Stefoni 2002	0	54	7	54	11.0%	0.07 [0.00, 1.14]	2002
Lord 2002	3	32	8	32	24.9%	0.38 [0.11, 1.29]	2002
<b>Total (95% CI)</b>		<b>219</b>		<b>219</b>	<b>100.0%</b>	<b>0.74 [0.24, 2.31]</b>	

Total (95% CI)

Total events

Heterogeneity: Tau<sup>2</sup> = 0.97; Chi<sup>2</sup> = 11.14, df = 4 (P = 0.03); I<sup>2</sup> = 64%

Test for overall effect: Z = 0.52 (P = 0.60)



### 1.1. Meta-analysis result for bleeding

### 1.2. Meta-analysis result for hemodialysis circuit thrombosis


Study or Subgroup	LMWH		UFH		Weight	Risk Ratio	Year
	Events	Total	Events	Total		IV, Random, 95% CI	
Schrader 1988	80	5045	69	5197	38.1%	1.19 [0.87, 1.64]	1988
Saltissi 1999	17	1111	35	1141	30.3%	0.50 [0.28, 0.89]	1999
Lord 2002	32	378	21	382	31.6%	1.54 [0.90, 2.62]	2002
<b>Total (95% CI)</b>		<b>6534</b>		<b>6720</b>	<b>100.0%</b>	<b>0.99 [0.56, 1.77]</b>	

Total (95% CI)

Total events

Heterogeneity: Tau<sup>2</sup> = 0.20; Chi<sup>2</sup> = 9.06, df = 2 (P = 0.01); I<sup>2</sup> = 78%

Test for overall effect: Z = 0.02 (P = 0.98)



## Key question 4.2.

Not applicable


## Key question 5.1.

Not applicable


## Key question 5.2.

### 1.1. Interdialytic weight gain

1.1.1. Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): RCT




1.1.2. Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): non-RCT




### 1.2. Predialysis BP


1.2.1. Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): RCT



### 1.2.2. Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): non-RCT




### 1.3. Antihypertensive medication: Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): RCT



#### Footnotes

(1) Aggregated equivalent dose units

### 1.4. Echocardiographic parameter: Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): non-RCT




Test for subarou differences: Chi<sup>2</sup> = 42.19, df = 3 (P < 0.00001). I<sup>2</sup> = 92.9%


## 1.5. Serum Na

1.5.1. Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): RCT






1.5.2. Low dialysate [Na<sup>+</sup>] (<138 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): non-RCT



1.6. Intradialytic hypotension: Low dialysate [Na<sup>+</sup>] (< 38 mEq/L) vs. conventional dialysate [Na<sup>+</sup>] (138 -140 mEq/L): RCT



### Key question 6.1.

Not applicable

### Key question 6.2.


Not applicable

### Key question 7.1.

Not applicable


### Key question 8.1.

1.1. Meta-analysis of dialysis treatment compared with supportive care for mortality in elderly ESRD patients.






1.2. Subgroup meta-analysis of dialysis treatments for mortality in prospective observational studies.



1.3. Subgroup meta-analysis of dialysis treatments for mortality in retrospective studies only.



**Key question 8.2.**

Not applicable